Mass balance and metabolite profiling of (14)C-guadecitabine in patients with advanced cancer

Purpose The objective of this mass balance trial was to determine the excretory pathways and metabolic profile of the novel anticancer agent guadecitabine in humans after administration of a (14)C-radiolabeled dose of guadecitabine. Experimental design Included patients received at least one cycle o...

Descripción completa

Detalles Bibliográficos
Autores principales: Roosendaal, Jeroen, Rosing, Hilde, Lucas, Luc, Gebretensae, Abadi, Huitema, Alwin D. R., van Dongen, Marloes G., Beijnen, Jos H., Oganesian, Aram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340650/
https://www.ncbi.nlm.nih.gov/pubmed/31605293
http://dx.doi.org/10.1007/s10637-019-00854-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340650/
https://www.ncbi.nlm.nih.gov/pubmed/31605293
http://dx.doi.org/10.1007/s10637-019-00854-9

Ejemplares similares